These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32910151)

  • 1. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.
    Pollack SM; Redman MW; Baker KK; Wagner MJ; Schroeder BA; Loggers ET; Trieselmann K; Copeland VC; Zhang S; Black G; McDonnell S; Gregory J; Johnson R; Moore R; Jones RL; Cranmer LD
    JAMA Oncol; 2020 Nov; 6(11):1778-1782. PubMed ID: 32910151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma.
    Livingston MB; Jagosky MH; Robinson MM; Ahrens WA; Benbow JH; Farhangfar CJ; Foureau DM; Maxwell DM; Baldrige EA; Begic X; Symanowski JT; Steuerwald NM; Anderson CJ; Patt JC; Kneisl JS; Kim ES
    Clin Cancer Res; 2021 Dec; 27(23):6424-6431. PubMed ID: 34475102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
    Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
    Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
    Kelly CM; Antonescu CR; Bowler T; Munhoz R; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Dholakia R; Ahmad H; Biniakewitz M; Condy M; Phelan H; Callahan M; Wong P; Singer S; Ariyan C; Bartlett EK; Crago A; Yoon S; Hwang S; Erinjeri JP; Qin LX; Tap WD; D'Angelo SP
    JAMA Oncol; 2020 Mar; 6(3):402-408. PubMed ID: 31971541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
    Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
    JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
    Cote GM; Choy E; Chen T; Marino-Enriquez A; Morgan J; Merriam P; Thornton K; Wagner AJ; Nathenson MJ; Demetri G; George S
    Eur J Cancer; 2020 Feb; 126():21-32. PubMed ID: 31896519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
    Tap WD; Wagner AJ; Schöffski P; Martin-Broto J; Krarup-Hansen A; Ganjoo KN; Yen CC; Abdul Razak AR; Spira A; Kawai A; Le Cesne A; Van Tine BA; Naito Y; Park SH; Fedenko A; Pápai Z; Soldatenkova V; Shahir A; Mo G; Wright J; Jones RL;
    JAMA; 2020 Apr; 323(13):1266-1276. PubMed ID: 32259228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial.
    Tian Z; Dong S; Zuo W; Li P; Zhang F; Gao S; Yang Y; Li C; Zhang P; Wang X; Wang J; Yao W
    Front Pharmacol; 2022; 13():987569. PubMed ID: 36582535
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
    Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL
    BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
    JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
    Stacchiotti S; Van der Graaf WTA; Sanfilippo RG; Marreaud SI; Van Houdt WJ; Judson IR; Gronchi A; Gelderblom H; Litiere S; Kasper B
    Cancer; 2022 Aug; 128(15):2932-2938. PubMed ID: 35561319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.
    Martin-Broto J; Hindi N; Lopez-Pousa A; Peinado-Serrano J; Alvarez R; Alvarez-Gonzalez A; Italiano A; Sargos P; Cruz-Jurado J; Isern-Verdum J; Dolado MC; Rincon-Pérez I; Sanchez-Bustos P; Gutierrez A; Romagosa C; Morosi C; Grignani G; Gatti M; Luna P; Alastuey I; Redondo A; Belinchon B; Martinez-Serra J; Sunyach MP; Coindre JM; Dei Tos AP; Romero J; Gronchi A; Blay JY; Moura DS
    JAMA Oncol; 2020 Apr; 6(4):535-541. PubMed ID: 32077895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
    Toulmonde M; Penel N; Adam J; Chevreau C; Blay JY; Le Cesne A; Bompas E; Piperno-Neumann S; Cousin S; Grellety T; Ryckewaert T; Bessede A; Ghiringhelli F; Pulido M; Italiano A
    JAMA Oncol; 2018 Jan; 4(1):93-97. PubMed ID: 28662235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
    Issels RD; Lindner LH; Verweij J; Wessalowski R; Reichardt P; Wust P; Ghadjar P; Hohenberger P; Angele M; Salat C; Vujaskovic Z; Daugaard S; Mella O; Mansmann U; Dürr HR; Knösel T; Abdel-Rahman S; Schmidt M; Hiddemann W; Jauch KW; Belka C; Gronchi A;
    JAMA Oncol; 2018 Apr; 4(4):483-492. PubMed ID: 29450452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
    Vinayak S; Tolaney SM; Schwartzberg L; Mita M; McCann G; Tan AR; Wahner-Hendrickson AE; Forero A; Anders C; Wulf GM; Dillon P; Lynce F; Zarwan C; Erban JK; Zhou Y; Buerstatte N; Graham JR; Arora S; Dezube BJ; Telli ML
    JAMA Oncol; 2019 Aug; 5(8):1132-1140. PubMed ID: 31194225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
    Sanfilippo R; Hayward RL; Musoro J; Benson C; Leahy MG; Brunello A; Blay JY; Steeghs N; Desar IME; Ali N; Hervieu A; Thway K; Marreaud S; Litiere S; Kasper B
    JAMA Oncol; 2022 Oct; 8(10):1420-1425. PubMed ID: 35980618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.